Patents Assigned to AstraZeneca
  • PYRIDINE COMPOUNDS
    Publication number: 20110166139
    Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
    Type: Application
    Filed: June 15, 2009
    Publication date: July 7, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
  • Quinoline derivatives
    Patent number: 7973164
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 5, 2011
    Assignee: AstraZeneca AB
    Inventors: Frederic Henri Jung, Patrick Ple
  • Chemical process for the preparation of an amido-phenoxybenzoic acid compound
    Patent number: 7973178
    Abstract: A process for making a compound of formula (I), which is useful as an intermediate to compounds which activate glucokinase, is described, (wherein P1, R1 and R2 are as defined in the description).
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: July 5, 2011
    Assignee: AstraZeneca AB
    Inventors: Phillip Anthony Hopes, Jeremy Stephen Parker, Bharti Patel, Matthew James Welham
  • Dibenzothiazepine Derivatives and Use Thereof
    Publication number: 20110160184
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Application
    Filed: June 18, 2009
    Publication date: June 30, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Dean Brown, Steven Wesolowski, Dan Widzowski, James R. Damewood, M. Edward Pierson, Jr., Michael Wood, Philip Edwards, James Hulsizer, Ashokkumar Bhikkappa Shenvi, James Campbell Muir
  • Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists
    Publication number: 20110160167
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 18, 2008
    Publication date: June 30, 2011
    Applicant: AstraZeneca AB
    Inventors: Håkan Bladh, Karl Edman, Thomas Hansson, Karolina Lawitz, Matti Lepistö, Tesfaledet Mussie
  • Cannabinoid Receptor Ligands
    Publication number: 20110160180
    Abstract: Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: August 15, 2008
    Publication date: June 30, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Sara Beha, William Brown, Shawn Johnstone, Ziping Liu, Daniel Pagé, Miroslaw Tomaszewski, Zhong-yong Wei, Shi Yi Yue
  • Preparation of Aminopyrimidine Compounds
    Publication number: 20110160455
    Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.
    Type: Application
    Filed: September 23, 2010
    Publication date: June 30, 2011
    Applicant: AstraZeneca UK Ltd.
    Inventors: Akio Matsushita, Mizuho Oda, Yasuhiro Kawachi, Jun-ichi Chika
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7968570
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: June 28, 2011
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Inhalation device
    Patent number: 7967011
    Abstract: Actuator for an inhaler for delivering medicament by inhalation, having a mouthpiece for guiding medicament to the mouth of a user; and a removable protection cap for the mouthpiece. The cap is secured to the mouthpiece by a cap retaining member that engages a mating recess in the mouthpiece outer periphery. The cap includes at least one release button arranged to provide an elastic deformation of the cap inner periphery that disengages the cap retaining member from the recess.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: June 28, 2011
    Assignee: AstraZeneca AB
    Inventors: Darren Hodson, Jorgen Rasmussen
  • Use of mGluR5 antagonists for the treatment of gerd
    Patent number: 7964609
    Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Anders Lehmann, Jan Mattsson, Thomas M. Stormann
  • Alkyl sulfoxide quinolines as NK-3 receptor ligands
    Patent number: 7964733
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Gerard M. Koether, Cristobal Alhambra, James Kang, Thomas R. Simpson, James Woods, Yan Li
  • Compounds 679
    Patent number: 7964616
    Abstract: The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3 and n are as defined in the specification
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Ebden, Simon David Guile
  • Chemical compounds
    Patent number: 7964618
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • Heteroarylbenzamide derivatives for use in the treatment of diabetes
    Patent number: 7964725
    Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Nathaniel George Martin, Darren Mckerrecher, Kurt Gordon Pike, Michael James Waring
  • METHOD OF TREATING SCHIZOPHRENIA AND OTHER DISORDERS
    Publication number: 20110144089
    Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
    Type: Application
    Filed: November 15, 2010
    Publication date: June 16, 2011
    Applicant: AstraZeneca AB
    Inventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Helen R. Winter, Raymond F. Suckow
  • Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders
    Publication number: 20110144331
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 16, 2011
    Applicant: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Film coating
    Patent number: 7959947
    Abstract: A film coating composition suitable for use in coating pharmaceutical formulations comprising a) an acrylic polymer dispersion, e.g. an ethylacrylate/methylmethacrylate copolymer such as Eudragit NE30D, b) a surfactant, c) sodium stearyl fumarate, and d) a water-containing liquid useful for the achievement of controlled release from pharmaceutical formulations such as tablets, pellets, etc.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: Arne Hölzer, Jan-Erik Löfroth, Staffan Schantz
  • Pharmaceutically active compounds containing tetrazolyl and triazolyl rings
    Patent number: 7960422
    Abstract: Compounds of formula (I) wherein R1 is as well as pharmaceutically acceptable salts, hydrates and/or enantiomers thereof are useful as compounds that exhibit activity at metabotropic glutamate receptors.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tao Xin
  • 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
    Patent number: 7960389
    Abstract: Compounds of general formula: wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin, Paul Jones, Daniel Page, Niklas Plobeck, Christopher Walpole
  • Process for the preparation and resolution of mandelic acid derivatives
    Patent number: 7960582
    Abstract: The present invention relates to a new process for the resolution of mandelic acid derivatives from racemic mandelic acid derivative mixtures by salt formation with chiral base cyclic amides; to the resolved mandelic acid cyclic amide salts (see, for example, formula IIa), as well as certain other metal and amine salts of the mandelic acid derivatives, and to the use of the resolved mandelic acid derivatives as intermediates suitable for large-scale manufacturing of, for example, pharmaceutical compounds; Formula IIa, wherein R is selected from CHF2, H, C1-6 Alkyl, CH2F, CHCl2 and CClF2; and wherein n is 0, 1 or 2; R1 is H or C1-6 Alkyl and X is H, halo or C1-6 Alkyl.
    Type: Grant
    Filed: November 25, 2004
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: Hans Jorgen Blixt, Bo Lars Gustaf Bosson, Roberto Guiseppe Paolo Gatti, Simone Zaramella, Michael William Senior, Kurt Vogtli, Andrea Zistler